


ASSESS PATIENT'S IMMUNITY TO FIGHT CANCER




Mary Jo, 60-year-old


- T3N1
- Descending colonic adenocarcinoma
- Mary Jo has an Immunoscore Low

**Would you recommend 3 months
or 6 months of chemotherapy?**

Evidence of Immunoscore®'s Predictive Value for the Duration of Treatment for Stage III Colon Cancer



Immunoscore High patients significantly benefit from longer duration of FOLFOX (6 vs 3 months).



For patients with Immunoscore Low, there is no significant benefit of FOLFOX treatment beyond 3 months.

Pages F, Andre T, Taieb J et al., Ann Oncol. 2020 Apr 12

Only patients with an Immunoscore High benefit from 6 months of FOLFOX, both in low (T1-3, N1) and high (T4 and/or N2) clinical risk groups.



How can Immunoscore® help with the management of stage III patients?

- Refines patients' risk profile
- Provides greater prognostic value than traditional measurements
- Validated Predictive Data in Stage III colon cancer



THE IMMUNE RESPONSE
TO CANCER DIAGNOSTICS

CONTACT & FOLLOW US

HalioDx Inc - Biotech Eight

737 N 5th St, 6th Floor - Richmond, VA 23219 - USA

Phone: + 1 (804) 944-2000 - Fax: +1 (804) 533-1504

✉ infos@haliodx.com



immunoscore-colon.com